Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.520 +0.500 (+8.31%)
Delayed Quote Updated: 9:42 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Myriad Genetics (NASDAQ:MYGN) Q3 Beats Estimates, Raises Guidance, and Strikes Prenatal Sale to Labcorp ↗
Via Chartmill
News headline image
Myriad Genetics Q3 Earnings Call Highlights ↗
Myriad Genetics (NASDAQ:MYGN) reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal... 
Via MarketBeat
Topics Earnings
News headline image
Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q3 2026 results beating Wall Street’s revenue expectations, but revenue fell by 1.5% year on y... 
Via StockStory
News headline image
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi... 
Via StockStory
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Russell 2000 stocks on our watchlist and 1 we ignore
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner
Check out the companies making headlines yesterday: Washington Trust Bancorp (NASDAQ:WASH): Regional bank Washington Trust Bancorp (NASDAQ:WASH) rose by 5% o... 
Via StockStory
Top US Stock Movers: Today's Session Gainers and Losers ↗
Via Chartmill
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session ↗
Via Chartmill
Gap Stocks: Gap-Up and Gap-Down Movers in Today's Session ↗
Via Chartmill
News headline image
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Pr... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Transaction to benefit patients through expanded access and support Myriad’s strategic priorities 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Small-Cap Stocks to Consider Right Now and 1 We Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r... 
Via StockStory
Topics Bonds Economy
News headline image
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin rais... 
Via StockStory
News headline image
1 Volatile Stock on Our Buy List and 2 We Question
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be... 
Via StockStory
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&... 
Via StockStory
Topics Bankruptcy
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Unprofitable Stocks to Research Further and 1 We Find Risky
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell by 6.2% on Tues... 
Via StockStory
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.